Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fepixnebart in diabetic peripheral neuropathic pain
NCT04476108Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2020
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of Fepixnebart in diabetic polyneuropathy (DPN), sponsored by Eli Lilly and Company. Started Jul 2020; status: completed.
02
Drugs
Fepixnebart
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT04476108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04476108.